<Page>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
-------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
June 13, 2002
-------------
CUBIST PHARMACEUTICALS, INC.
----------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 0-21379 22-3192085
- --------------------------------------------------------------------------------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
65 HAYDEN AVENUE, LEXINGTON, MASSACHUSETTS 02421
------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (781) 860-8660
--------------
<Page>
ITEM 5. OTHER EVENTS.
------------
The Annual Meeting of Stockholders of the Registrant was held on June
13, 2002. Of the 28,437,801 shares outstanding as of April 15, 2002, the record
date, 23,842,936 shares (83.84%) were present or represented by proxy at the
annual meeting.
1. The table below presents the results of the election to the
Registrant's board of directors:
<Table>
<Caption>
Nominee Votes For Withheld
------- --------- --------
John K. Clarke 23,587,530 255,406
Scott M. Rocklage 23,765,652 77,284
</Table>
Since the time of the mailing of the Registrant's proxy statement, Dr.
Paul Schimmel chose not to stand for re-election as a director of the
Registrant. Therefore, although Dr. Schimmel appeared as a nominee in the
Registrant's proxy statement, he did not stand for re-election as a Class III
director. The Class III director seat previously held by Dr. Schimmel is
currently vacant.
2. The stockholders ratified, adopted and approved the Amended and
Restated 2000 Equity Incentive Plan. This proposal received 15,608,104 votes
for, 8,203,890 votes against, 30,942 shares abstaining and no broker non-votes.
3. The stockholders ratified, adopted and approved the 2002 Directors'
Stock Option Plan. This proposal received 20,977,721 votes for, 2,830,509 votes
against, 34,706 shares abstaining and no broker non-votes.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
---------------------------------
None
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CUBIST PHARMACEUTICALS, INC.
By: /s/ Thomas A. Shea
------------------------------------------
Thomas A. Shea
Vice President Finance and
Administration, Chief Financial
Officer, Treasurer
Dated: June 14, 2002